Drug Trial Radar · NCT02365597
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
239
Actual
Start
Apr 22, 2015
Primary completion
Sep 15, 2022
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Feb 19, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the objective response rate (complete response \[CR\]+ partial response \[PR\]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.
Conditions
- Urothelial Cancer
Interventions
ErdafitinibDrug
8 mg orally once daily for 28 days on a 28 day cycle.
MidazolamDrug
Participants who enrolled in DDI substudy will receive pretreatment with single dose of midazolam on Day -2 and single dose of midazolam on Day 13.
MetforminDrug
Participants who enrolled in DDI substudy will receive pretreatment with single dose of metformin on Day -1 and single dose of metformin on Day 14.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Main Study: Percentage of Participants With Best (Overall) Objective ResponseTime frame: From Cycle 1 Day 1 up to 6 years 2 months
- Drug-Drug Interaction (DDI) Substudy: Maximum Observed Plasma Concentration (Cmax) of Midazolam Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -2 (predose) up to Day 13 post dose
- Drug-Drug Interaction (DDI) Substudy: Maximum Observed Plasma Concentration (Cmax) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
- Drug-Drug Interaction (DDI) Substudy: Maximum Observed Plasma Concentration (Cmax) of Metformin Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
- Drug-Drug Interaction (DDI) Substudy: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of Midazolam Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
- Drug-Drug Interaction (DDI) Substudy: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
- Drug-Drug Interaction (DDI) Substudy: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of Metformin Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
- Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC[0-last]) of Midazolam Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
- Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC[0-last]) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
- Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC[0-last]) of Metformin Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
- Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Infinite Time (AUC[0-Infinity]) of Midazolam Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
- Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Infinite Time (AUC[0-Infinity]) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
- Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Infinite Time (AUC[0-Infinity]) of Metformin Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
Locations
105 sites in 15 countries. Site status is shown where the registry gives one.
Site not named
Sedona, Arizona
Site not named
Los Angeles, California
Site not named
Orange, California
Site not named
Sacramento, California
Site not named
Stanford, California
Site not named
Aurora, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Chicago, Illinois
Site not named
Iowa City, Iowa
Site not named
Louisville, Kentucky
Site not named
Minneapolis, Minnesota
Site not named
Omaha, Nebraska
Site not named
Las Vegas, Nevada
Site not named
New York, New York
Site not named
Charlotte, North Carolina
Site not named
Medford, Oregon
Site not named
Tualatin, Oregon
Site not named
Hershey, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Site not named
Myrtle Beach, South Carolina
Site not named
Nashville, Tennessee
Site not named
Dallas, Texas
Site not named
Denton, Texas
Site not named
Houston, Texas
Site not named
Hampton, Virginia
Site not named
Graz, Austria
Site not named
Linz, Austria
Site not named
Vienna, Austria
Site not named
Aalst, Belgium
Site not named
Brussels, Belgium
Site not named
Charleroi, Belgium
Site not named
Ghent, Belgium
Site not named
Wilrijk, Belgium
Site not named
Angers, France
Site not named
Bordeaux, France
Site not named
Caen Cédex 05, France
Site not named
Dijon, France
Site not named
Lyon, France
Site not named
Nice, France
Site not named
Nîmes, France
Showing 40 of 105 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.